Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphatidic acid (LPA), present in ascitic fluid, motivates the enlargement of malignant ovarian tumors by raising the appearance of vascular endothelial growth factor (VEGF) in ovarian cancer cells. Ovarian cancer cell progress is repressed by alendronate, a nitrogen containing biophosphate which attenuate the establishment of Rho by blocking the mevalonate pathway. Cancer is still one of the major problems found in medical practice and in spite of clear advances in diagnosis and treatment, it remains an important cause of suffering and death in human and veterinary pathology. So there is a need to search for new approaches and ideas in this field. As of January 1, 2014, there were 14.5 million estimated survivors of the 10 most prevalent cancer sites among males and females in the United States [1]. One in four Americans will die of cancer [2] in the next years. Prevention, early diagnosis, surgery, radiotherapy, chemotherapy, immunotherapy and targeted drugs have made substantial contributions, and will continue to do so in the foreseeable future. But there is more that can be done. Since cancer is a very complex disease, it is reasonable to think that future solutions can only emerge from very sophisticated and expensive research. However, we dare to suggest that, right now, there are simple approaches that may be quite useful as complementary treatments in the management of cancer, just by re-positioning or repurposing, already approved existing drugs.
Authors and Affiliations
Tomas Koltai
Plasma Lysophasphatidic Acid Level: A Diagnostic Tool and Benchmark for Ovarian Cancer Management
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphat...
Immunotherapy in Some Types of Tumors
Immunotherapy exerts its antitumor action by stimulating the response immune response of patients to cancer, unlike classic treatments, which directly attack the tumor. Previously immunotherapy was limited to patients in...
Main Components of Liquid Biopsy are Greater than it Seems?
Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to met...
Aspirin, Vascular Disease and Cancer: 50 Years of Controversy and the Jury’s Still Out!
The story of aspirin and vascular disease starts with John O Brien, a haematologist in Portsmouth in the 1960s, who reported that the ingestion of 150mg of aspirin substantially reduced the aggregation of platelets [1]....
A Note on Mushroom Immunomodulation and its Potential on Prevention of Cancer
Patterns of diseases and resulting well-being, morbidity and mortality have changed considerably in the last decades namely in developed countries. Infection-contagious diseases are no longer a major threat and other chr...